Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Upcoming Result Date: May 25, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discovery themes featuring this stockFermenta Biotech Ltd (FERMENTA) is currently trading at 305.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fermenta Biotech Limited manufactures and supplies scientifically-validated nutritional ingredients, APIs, enzymes, and green-chemistry solutions to global pharmaceutical, nutraceutical, food, veterinary and animal feed customers, operating manufacturing sites across India and a German toll manufacturing collaboration, supported by an R&D hub and multiple global regulatory certifications. The company posted consolidated 9M FY26 revenue of INR 421.2 crore, up 25% year‑on‑year, driven by a 51% increase in Human Vitamin D3 and a 46% rise in Animal Nutrition volumes, while Q3 showed sequential revenue improvement despite YoY moderation linked to a large one-off real estate income in the prior year. Fermenta demonstrates strong operating leverage: raw-materials reduced to 38% of revenue from 53% in FY24, manufacturing expense fell to 11% in 9M FY26, and finance costs declined to 2%, indicating procurement efficiency, capacity utilisation gains, and deleveraging that position Fermenta for margin expansion as volumes continue to scale. R&D and product differentiation are tangible growth drivers: Fermenta holds patents including spray-dried 100,000 IU/g Vitamin D3 with CEP certification, plant-based VITADEE™ Green, and enzyme/IP commercialization plans such as Calcefediol and Penmox technology, giving Fermenta Biotech Limited premium product positioning for regulated European and pharmaceutical markets. Customer diversification is a strength: the largest customer is only 7% of revenue and the top 10 customers account for 43%, while geographic mix is shifting toward Europe (now 32%), reflecting Fermenta’s ability to expand institutional and regulated-market sales beyond domestic reliance.
Over the past 52 weeks, Fermenta Biotech Ltd has traded between a low of ₹256.40 and a high of ₹399.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fermenta Biotech Ltd has a market capitalization of approximately 890.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fermenta Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.24 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 890.73 Cr, Fermenta Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fermenta Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fermenta Biotech Ltd is 10.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
287.70 | 998 Cr | 23.21 | 12.89 | 0.00 | 51.51 | 27.98 | 10.39 | ||
1396.80 | 954 Cr | -116.46 | 2.96 | 0.07 | -2.54 | -1.83 | -4.45 | ||
100.92 | 927 Cr | -53.23 | 2.67 | 0.50 | -7.10 | -3.47 | -2.99 | ||
760.85 | 897 Cr | 24.24 | 2.55 | 0.07 | 10.54 | 16.04 | 7.98 | ||
307.00 | 891 Cr | 10.24 | 2.28 | 0.82 | 28.46 | 27.38 | 13.04 | ||
625.00 | 799 Cr | 44.96 | 4.90 | 0.00 | 10.90 | 14.23 | 8.56 | ||
163.75 | 788 Cr | 30.61 | 1.49 | 0.00 | 4.85 | 6.56 | 2.83 | ||
| Median: 7 Co. | — | 307.00 | 897 Cr | 23.21 | 2.67 | 0.07 | 10.54 | 14.23 | 7.98 |
Investor Meeting
Company notified BSE of a physical one-to-one investor meeting in Mumbai on May 28, 2026; investor presentation will be uploaded after the Board meeting on May 26, 2026; no UPSI to be discussed.
Board Meeting Notice
Fermenta Biotech's Board will meet on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and FY ended Mar 31, 2026, and to consider recommendation of a final equity dividend; trading window closed.
Board Meeting Notice
Fermenta Biotech will hold a board meeting on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, and to consider a final equity dividend.
Bearish
4
Neutral
6
Bullish
4
Bearish
21
Neutral
6
Bullish
19
Bearish
17
Neutral
0
Bullish
15
Fermenta Biotech Limited manufactures and supplies scientifically-validated nutritional ingredients, APIs, enzymes, and green-chemistry solutions to global pharmaceutical, nutraceutical, food, veterinary and animal feed customers, operating manufacturing sites across India and a German toll manufacturing collaboration, supported by an R&D hub and multiple global regulatory certifications.
The company posted consolidated 9M FY26 revenue of INR 421.2 crore, up 25% year‑on‑year, driven by a 51% increase in Human Vitamin D3 and a 46% rise in Animal Nutrition volumes, while Q3 showed sequential revenue improvement despite YoY moderation linked to a large one-off real estate income in the prior year.
Fermenta demonstrates strong operating leverage: raw-materials reduced to 38% of revenue from 53% in FY24, manufacturing expense fell to 11% in 9M FY26, and finance costs declined to 2%, indicating procurement efficiency, capacity utilisation gains, and deleveraging that position Fermenta for margin expansion as volumes continue to scale.
R&D and product differentiation are tangible growth drivers: Fermenta holds patents including spray-dried 100,000 IU/g Vitamin D3 with CEP certification, plant-based VITADEE™ Green, and enzyme/IP commercialization plans such as Calcefediol and Penmox technology, giving Fermenta Biotech Limited premium product positioning for regulated European and pharmaceutical markets.
Customer diversification is a strength: the largest customer is only 7% of revenue and the top 10 customers account for 43%, while geographic mix is shifting toward Europe (now 32%), reflecting Fermenta’s ability to expand institutional and regulated-market sales beyond domestic reliance.
Pharmaceuticals & Biotechnology
Pharmaceuticals
900 Cr
Low Risk
10.3
34.3
0.3
2.3
399.00
256.40
Sales CAGR
Profit CAGR
ROE
ROCE
